Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
11 Jan 2024
11 Jan 2024
Historique:
revised:
27
11
2023
received:
03
11
2023
accepted:
02
01
2024
medline:
12
1
2024
pubmed:
12
1
2024
entrez:
12
1
2024
Statut:
aheadofprint
Résumé
Noninvasive tests (NITs) have been proposed as an alternative to liver biopsy for diagnosing liver cirrhosis. The evidence of NIT performance in patients with chronic hepatitis D (CHD) is limited. To evaluate the diagnostic performance of liver stiffness measurement (LSM) and other NITs in CHD patients. We evaluated the diagnostic performance of LSM by transient elastography for the detection of liver cirrhosis in a retrospective, multicentre cohort of 144 CHD patients with paired (±6 months) LSM and liver biopsies. Cirrhosis was diagnosed histologically in 22 patients (15.3%). Mean LSM was significantly higher in patients with cirrhosis compared to those without fibrosis (23.4 vs 10.2 kPa, p < 0.0001) or with intermediate fibrosis (23.4 vs 13.5 kPa, p < 0.0001). In the detection of liver cirrhosis, LSM was superior to other NITs (AUROCs: 0.89 [LSM], 0.87 [D4FS], 0.74 [APRI], 0.73 [FIB-4], and 0.69 [AAR]). The optimal cut-off for identifying patients with liver cirrhosis was ≥15.2 kPa (Se 91%, Sp 84%, PPV 50%, NPV 98%). The ideal cut-off for diagnosing non-advanced liver fibrosis (Metavir ≤2) was <10.2 kPa (Se 55%, Sp 86%, PPV 90%, NPV 45%), correctly identifying 90% of patients. Data were validated in an independent cohort of 132 CHD patients. LSM is a useful tool for identifying patients at risk for liver cirrhosis and is superior to other NITs. The cut-offs of <10.2 and < 15.2 kPa reliably diagnose non-advanced liver fibrosis and exclude cirrhosis in the majority of patients. However, LSM cannot completely replace liver biopsy in CHD patients.
Sections du résumé
BACKGROUND
BACKGROUND
Noninvasive tests (NITs) have been proposed as an alternative to liver biopsy for diagnosing liver cirrhosis. The evidence of NIT performance in patients with chronic hepatitis D (CHD) is limited.
AIMS
OBJECTIVE
To evaluate the diagnostic performance of liver stiffness measurement (LSM) and other NITs in CHD patients.
METHODS
METHODS
We evaluated the diagnostic performance of LSM by transient elastography for the detection of liver cirrhosis in a retrospective, multicentre cohort of 144 CHD patients with paired (±6 months) LSM and liver biopsies.
RESULTS
RESULTS
Cirrhosis was diagnosed histologically in 22 patients (15.3%). Mean LSM was significantly higher in patients with cirrhosis compared to those without fibrosis (23.4 vs 10.2 kPa, p < 0.0001) or with intermediate fibrosis (23.4 vs 13.5 kPa, p < 0.0001). In the detection of liver cirrhosis, LSM was superior to other NITs (AUROCs: 0.89 [LSM], 0.87 [D4FS], 0.74 [APRI], 0.73 [FIB-4], and 0.69 [AAR]). The optimal cut-off for identifying patients with liver cirrhosis was ≥15.2 kPa (Se 91%, Sp 84%, PPV 50%, NPV 98%). The ideal cut-off for diagnosing non-advanced liver fibrosis (Metavir ≤2) was <10.2 kPa (Se 55%, Sp 86%, PPV 90%, NPV 45%), correctly identifying 90% of patients. Data were validated in an independent cohort of 132 CHD patients.
CONCLUSIONS
CONCLUSIONS
LSM is a useful tool for identifying patients at risk for liver cirrhosis and is superior to other NITs. The cut-offs of <10.2 and < 15.2 kPa reliably diagnose non-advanced liver fibrosis and exclude cirrhosis in the majority of patients. However, LSM cannot completely replace liver biopsy in CHD patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update. J Hepatol. 2021;75(3):659-689. https://doi.org/10.1016/J.JHEP.2021.05.025
Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48-54. https://doi.org/10.1002/HEP.20506
Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29(2):242-247. https://doi.org/10.1111/J.1478-3231.2008.01802.X
Chon YE, Choi EH, Song KJ, Park JY, Kim DY, Han KH, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PloS One. 2012;7(9):e44930. https://doi.org/10.1371/JOURNAL.PONE.0044930
Trebicka J, Gu W, De Ledinghen V, Aubé C, Krag A, Praktiknjo M, et al. Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. Gut. 2021;71(2):402-414. https://doi.org/10.1136/gutjnl-2020-323419
Friedrich-Rust M, Poynard T, Castera L. Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol. 2016;13(7):402-411. https://doi.org/10.1038/NRGASTRO.2016.86
Sandmann L, Wedemeyer H. New treatments for chronic hepatitis B virus/hepatitis D virus infection. Clin Liver Dis. 2021;25(4):831-839. https://doi.org/10.1016/j.cld.2021.06.011
Sandmann L, Wedemeyer H. Interferon-based treatment of chronic hepatitis D. Liver Int. 2023;43 Suppl 1:69-79. https://doi.org/10.1111/liv.15410
Lampertico P, Roulot D, Wedemeyer H. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies. J Hepatol. 2022;77(5):1422-1430. https://doi.org/10.1016/J.JHEP.2022.06.010
Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, et al. A phase 3, randomized trial of Bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389(1):22-32. https://doi.org/10.1056/nejmoa2213429
Lutterkort GL, Wranke A, Yurdaydin C, Budde E, Westphal M, Lichtinghagen R, et al. Non-invasive fibrosis score for hepatitis delta. Liver Int. 2017;37(2):196-204. https://doi.org/10.1111/LIV.13205
Takyar V, Surana P, Kleiner DE, Wilkins K, Hoofnagle JH, Liang TJ, et al. Noninvasive markers for staging fibrosis in chronic delta hepatitis. Aliment Pharmacol Ther. 2017;45(1):127-138. https://doi.org/10.1111/APT.13834
Etzion O, Yardeni D, Palom A, et al. Noninvasive tests for detection of biopsy-proven cirrhosis in chronic hepatitis D infected patients are suboptimal. AASLD-The Liver Meeting 2020 (poster presentation).
Da BL, Surana P, Takyar V, Kleiner DE, Heller T, Koh C. Vibration-controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection. J Viral Hepat. 2020;27(4):428-436. https://doi.org/10.1111/jvh.13235
Brunetto MR, Ricco G, Negro F, Wedemeyer H, Yurdaydin C, Asselah T, et al. Clinical practice guidelines on Hepatitis Delta virus. J Hepatol. 2023;79(2):433-460. https://doi.org/10.1016/J.JHEP.2023.05.001
Ghany MG, Buti M, Lampertico P, Lee HM. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in, chronic hepatitis B and D-report from the 2022 AASLD-EASL HBV/HDV treatment endpoints conference. J Hepatol. 2023;79(5):1254-1269. https://doi.org/10.1016/j.jhep.2023.06.002
Rozario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. J Hepatol. 2003;38(2):223-229. https://doi.org/10.1016/S0168-8278(02)00357-4
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325. https://doi.org/10.1002/HEP.21178
Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-526. https://doi.org/10.1053/jhep.2003.50346
Williams ALB, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to Cirrhosis. Gastroenterology. 1988;95(3):734-739. https://doi.org/10.1016/S0016-5085(88)80022-2
Da BL, Surana P, Kleiner DE, Heller T, Koh C. The Delta-4 fibrosis score (D4FS): a novel fibrosis score in chronic hepatitis D. Antiviral Res. 2020;174:104691. https://doi.org/10.1016/j.antiviral.2019.104691
Kim BK, Kim DY, Park JY, Ahn SH, Chon CY, Kim JK, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010;30(4):546-553. https://doi.org/10.1111/j.1478-3231.2009.02192.x
Kalkan Ç, Yılmaz Y, Erdoğan BD, Savaş B, Yurdcu E, Çalışkan A, et al. Non-invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta. J Viral Hepat. 2023;30(5):406-416. https://doi.org/10.1111/jvh.13806
Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat. 2007;14(5):360-369. https://doi.org/10.1111/J.1365-2893.2006.00811.X
Chan HLY, Wong GLH, Choi PCL, Chan AWH, Chim AML, Yiu KKL, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2009;16(1):36-44. https://doi.org/10.1111/j.1365-2893.2008.01037.x
Kim SU, Kim JK, Park YN, Han KH. Discordance between liver biopsy and fibroscan® in assessing liver fibrosis in chronic hepatitis b: risk factors and influence of necroinflammation. PloS One. 2012;7(2):e32233. https://doi.org/10.1371/journal.pone.0032233
Yang AH, Yardeni D, Hercun J, Kleiner DE, Ling A, Marko J, et al. Shear wave elastography: how well does it perform in chronic hepatitis D virus infection? J Viral Hepat. 2022;29(12):1127-1133. https://doi.org/10.1111/JVH.13745
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII-renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-974. https://doi.org/10.1016/j.jhep.2021.12.022
Sandmann L, Berg T, Deterding K, Fischer N, Hinrichsen H, Petersen J, et al. Antiviral therapy of chronic hepatitis D virus infection - addendum to the S3 guideline “prophylaxis, diagnosis and therapy of hepatitis B virus infection” of the German Society for Gastroenterology, digestive and metabolic diseases (DGVS). Z Gastroenterol. 2023;61(12):e715-e732. https://doi.org/10.1055/A-2181-3345